IsoRay to distribute Oncura's I-125 brachytherapy seed

IsoRay, Inc. (Amex: ISR) announced today that it has signed a distribution agreement with Oncura to distribute the I-125 brachytherapy seed, OncoSeed™.

Dwight Babcock, Chairman and CEO stated, “By adding I-125 seeds to our prostate product offering we can now be a full service provider to our customers. OncoSeed brings with it a substantial and well documented track record of efficacy. While we believe that Cesium-131 adds an important new dimension to brachytherapy for a variety of anatomic sites including prostate, we see strategic value in supporting our customers that have not yet converted all their practice to Cesium-131.”

Mr. Babcock added, “We believe the ability to offer I-125 seeds will allow us to expand our Cesium-131 sales through GPO contracts which require multiple sources from a single provider. Previously, by not having two sources, we have been excluded from bidding on large GPO contracts and offering Cesium-131. The ability to obtain GPO contracts should open up a large group of physicians who want to use our Cesium-131 brachytherapy seeds.”

OncoSeed, known by physicians as Model 6711, has been available since it was launched in 1993. It has the largest market share of any I-125 brachytherapy seed worldwide.

Mr. Babcock concluded, “This is an important step to support our physician partners and this agreement allows IsoRay to supply I-125 seeds to its Canadian partner, Inter V Medical, thus providing additional revenue and margins to IsoRay.”

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Does IBD affect cancer risk?